MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway
Wang, ShuyangNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationZhou, Chunxian, Fengyun Cui, Jiali Li, Diyi Wang, Yingze Wei, Ying Wu, Jiping Wang, Hongguang Zhu, and Shuyang Wang. 2017. “MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway.” Oncotarget 8 (30): 49534-49547. doi:10.18632/oncotarget.17743. http://dx.doi.org/10.18632/oncotarget.17743.
AbstractAlthough 5-year survival rate of non-metastatic colorectal cancer (CRC) is high, about 10% of patients in stage I and II still develop into metastatic CRC and eventually die after resection. Currently, there is no effective biomarker for predicting the prognosis of non-metastatic CRC in clinical practice. In this study, we identified miR-650 as a biomarker for prognosis prediction. We observed that the expression of miR-650 in tumor tissues had a positive association with overall survival. MiR-650 inhibited cell growth and invasion in vitro and in vivo. Furthermore, miR-650 targeted AKT2 and repressed the activation of the AKT pathway (AKT2/GSK3β/E-cadherin). Thus it induced the translocation of E-cadherin and β-catenin in cancer cells. Our results highlight the potential of miR-650 as a prognostic prediction biomarker and therapeutic target in non-metastatic CRC via inhibition of the AKT2/GSK3β/E-cadherin pathway.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34375129
- HMS Scholarly Articles